NASDAQ
23.14USD
+0.65 (+2.89%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.7B
P/E
—
EPS
—
Beta
1.14
52W range
11.51-29.75
Day range
22.63–23.36
Open
22.66
Prev close
22.49
Volume
606.3K
Avg volume
705.7K
Dividend
0.00
IPO
2017-04-28
https://www.globenewswire.com/news-release/2026/06/14/3311472/0/en/Zymeworks-Presents-New-Phase-1-Data-for-Folate-Receptor-Alpha-Targeting-ADC-ZW191-at-ESMO-Gynaecological-Cancers-Congress-2026.html · 6/14/2026+0.80
https://www.globenewswire.com/news-release/2026/05/14/3295346/0/en/zymeworks-announces-share-repurchase-program-of-up-to-125-million-of-its-common-stock.html · 5/14/2026+0.60
https://www.marketbeat.com/instant-alerts/zymeworks-q1-earnings-call-highlights-2026-05-09/ · 5/9/2026+0.40
https://seekingalpha.com/article/4901858-zymeworks-inc-zyme-q1-2026-earnings-call-transcript · 5/9/2026+0.00
https://www.defenseworld.net/2026/04/26/zymeworks-highlights-royalty-fueled-pivot-at-bloom-burton-eyes-multibillion-dollar-ziihera.html · 4/26/2026
https://www.fool.com/coverage/filings/2026/02/22/investor-slashes-usd70-million-from-zymeworks-as-stock-jumps-60-in-a-year/ · 2/22/2026+0.20
https://www.globenewswire.com/news-release/2026/01/11/3216504/0/en/Zymeworks-Outlines-Strategic-Priorities-and-Outlook-for-2026.html · 1/11/2026+0.80
https://www.defenseworld.net/2025/12/20/zymeworks-inc-zyme-shares-purchased-by-assenagon-asset-management-s-a.html · 12/20/2025+0.60
https://www.globenewswire.com/news-release/2025/12/02/3198428/0/en/Zymeworks-Announces-Participation-in-Upcoming-Conferences.html · 12/2/2025+0.30
https://seekingalpha.com/article/4845719-zymeworks-a-lot-of-moving-parts · 11/19/2025+0.80
https://seekingalpha.com/article/4832792-zymeworks-inc-zyme-shareholder-analyst-call-transcript · 10/24/2025+0.00
https://www.zacks.com/stock/news/2768568/zymeworks-inc-zyme-is-a-great-momentum-stock-should-you-buy?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_10-2768568 · 10/14/2025+1.00
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
